EMA-话题@MedSci

#EMA#

580篇内容 | 2455人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317634, encodeId=ae4a131e6341c, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=J Hematol Oncol：术后循环肿瘤DNA（ctDNA）可用于II/III其结直肠癌患者复发风险预测指标, objectType=article, longId=211566, objectId=9376211566f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9376211566f4, replyNumber=0, likeNumber=82, createdTime=2021-05-21, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9376211566f4, moduleTitle=J Hematol Oncol：术后循环肿瘤DNA（ctDNA）可用于II/III其结直肠癌患者复发风险预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9376211566f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317633, encodeId=a0eb131e633c3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Sci Trans Med：Tau抗体semorinemab I期临床安全, objectType=article, longId=211480, objectId=b1742114801f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1742114801f, replyNumber=0, likeNumber=74, createdTime=2021-05-19, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1742114801f, moduleTitle=Sci Trans Med：Tau抗体semorinemab I期临床安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1742114801f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317632, encodeId=9707131e632af, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法, objectType=article, longId=211074, objectId=1a872110e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a872110e4ea, replyNumber=0, likeNumber=85, createdTime=2021-05-12, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a872110e4ea, moduleTitle=Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a872110e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317631, encodeId=646e131e63152, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=NEJM：Donanemab治疗早期阿尔茨海默病临床研究获得积极结果, objectType=article, longId=210903, objectId=bcfc210903e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcfc210903e7, replyNumber=0, likeNumber=72, createdTime=2021-05-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcfc210903e7, moduleTitle=NEJM：Donanemab治疗早期阿尔茨海默病临床研究获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcfc210903e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317630, encodeId=dd77131e6303e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：早期识别血管内皮细胞病变并减轻其进展或可改善COVID-19患者的结局, objectType=article, longId=210522, objectId=91c121052234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91c121052234, replyNumber=0, likeNumber=60, createdTime=2021-04-28, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91c121052234, moduleTitle=Lancet Haematol：早期识别血管内皮细胞病变并减轻其进展或可改善COVID-19患者的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91c121052234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317629, encodeId=4e9a131e6296f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Am J Hematol：cfDNA技术检测华氏巨球蛋白血症中MYD88 L265P和CXCR4 S338X突变, objectType=article, longId=210464, objectId=ad80210464cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad80210464cb, replyNumber=0, likeNumber=73, createdTime=2021-04-27, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad80210464cb, moduleTitle=Am J Hematol：cfDNA技术检测华氏巨球蛋白血症中MYD88 L265P和CXCR4 S338X突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad80210464cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317628, encodeId=51ec131e6287a, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定, objectType=article, longId=210265, objectId=27f521026528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f521026528, replyNumber=0, likeNumber=49, createdTime=2021-04-23, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f521026528, moduleTitle=安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f521026528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317627, encodeId=6438131e627fb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧盟EMA发现强生新冠疫苗可能与血栓有关，但表示获益大于风险, objectType=article, longId=210253, objectId=93e8210253cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e8210253cb, replyNumber=0, likeNumber=114, createdTime=2021-04-22, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e8210253cb, moduleTitle=欧盟EMA发现强生新冠疫苗可能与血栓有关，但表示获益大于风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e8210253cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317626, encodeId=adf3131e62607, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Am J Hematology: 新冠患者接受抗凝治疗可以减少死亡率, objectType=article, longId=210060, objectId=fff72100607b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fff72100607b, replyNumber=0, likeNumber=71, createdTime=2021-04-17, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fff72100607b, moduleTitle=Am J Hematology: 新冠患者接受抗凝治疗可以减少死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fff72100607b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317625, encodeId=8d40131e625d6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA就使用regdanvimab治疗COVID-19，持谨慎意见, objectType=article, longId=209108, objectId=9faa2091087c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9faa2091087c, replyNumber=0, likeNumber=57, createdTime=2021-03-29, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9faa2091087c, moduleTitle=EMA就使用regdanvimab治疗COVID-19，持谨慎意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9faa2091087c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317624, encodeId=d652131e6242f, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, objectType=article, longId=209073, objectId=c97e2090e362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97e2090e362, replyNumber=0, likeNumber=56, createdTime=2021-03-29, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97e2090e362, moduleTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c97e2090e362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317623, encodeId=1d72131e623a1, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=礼来的donanemab治疗阿尔茨海默症，结果好坏参半, objectType=article, longId=208445, objectId=702020844586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=702020844586, replyNumber=0, likeNumber=62, createdTime=2021-03-17, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=702020844586, moduleTitle=礼来的donanemab治疗阿尔茨海默症，结果好坏参半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=702020844586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317622, encodeId=c4d0131e622dd, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=J Hematol Oncol：KMT2家族基因突变可预测癌症患者对免疫检查点治疗的反应性, objectType=article, longId=207918, objectId=543420e91803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=543420e91803, replyNumber=0, likeNumber=84, createdTime=2021-03-07, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=543420e91803, moduleTitle=J Hematol Oncol：KMT2家族基因突变可预测癌症患者对免疫检查点治疗的反应性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=543420e91803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317621, encodeId=d7a5131e62138, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA接受Somatrogon的市场营销申请，以治疗生长激素缺乏症患儿, objectType=article, longId=207703, objectId=22ff20e70355, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ff20e70355, replyNumber=0, likeNumber=84, createdTime=2021-03-01, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ff20e70355, moduleTitle=EMA接受Somatrogon的市场营销申请，以治疗生长激素缺乏症患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ff20e70355)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317620, encodeId=dc48131e62049, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=20价肺炎球菌疫苗，即将获得EMA的批准, objectType=article, longId=207691, objectId=de5620e69191, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de5620e69191, replyNumber=0, likeNumber=56, createdTime=2021-02-28, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de5620e69191, moduleTitle=20价肺炎球菌疫苗，即将获得EMA的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de5620e69191)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317619, encodeId=471f131e619c8, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, objectType=article, longId=207517, objectId=3e5020e5170d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5020e5170d, replyNumber=0, likeNumber=65, createdTime=2021-02-25, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5020e5170d, moduleTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5020e5170d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317618, encodeId=11a3131e618f8, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Neurol：Tau蛋白单克隆抗体Tilavonemab对进行性核上性麻痹治疗无效！, objectType=article, longId=207468, objectId=eaa720e4686f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaa720e4686f, replyNumber=0, likeNumber=66, createdTime=2021-02-24, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaa720e4686f, moduleTitle=Lancet Neurol：Tau蛋白单克隆抗体Tilavonemab对进行性核上性麻痹治疗无效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaa720e4686f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317617, encodeId=f605131e617e4, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Sparsentan治疗IgA肾病（IgAN），EMA已授予Sparsentan“孤儿药称号”, objectType=article, longId=207390, objectId=460c20e390d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460c20e390d3, replyNumber=0, likeNumber=83, createdTime=2021-02-22, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460c20e390d3, moduleTitle=Sparsentan治疗IgA肾病（IgAN），EMA已授予Sparsentan“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460c20e390d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317616, encodeId=38ff131e61639, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=胃肠道间质瘤（GIST）的治疗或迎新突破，EMA授予Ilixadencel“孤儿药资格”, objectType=article, longId=207384, objectId=922f20e38487, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=922f20e38487, replyNumber=0, likeNumber=59, createdTime=2021-02-22, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=922f20e38487, moduleTitle=胃肠道间质瘤（GIST）的治疗或迎新突破，EMA授予Ilixadencel“孤儿药资格”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=922f20e38487)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317615, encodeId=85a8131e6156e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, objectType=article, longId=206905, objectId=e68520690580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68520690580, replyNumber=0, likeNumber=99, createdTime=2021-02-09, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68520690580, moduleTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e68520690580)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

J Hematol Oncol：术后循环肿瘤DNA（ctDNA）可用于II/III其结直肠癌患者复发风险预测指标

2021-05-21

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Sci Trans Med：Tau抗体semorinemab I期临床安全

2021-05-19

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法

2021-05-12

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

NEJM：Donanemab治疗早期阿尔茨海默病临床研究获得积极结果

2021-05-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：早期识别血管内皮细胞病变并减轻其进展或可改善COVID-19患者的结局

2021-04-28

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Am J Hematol：cfDNA技术检测华氏巨球蛋白血症中MYD88 L265P和CXCR4 S338X突变

2021-04-27

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定

2021-04-23

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧盟EMA发现强生新冠疫苗可能与血栓有关，但表示获益大于风险

2021-04-22

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Am J Hematology: 新冠患者接受抗凝治疗可以减少死亡率

2021-04-17

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA就使用regdanvimab治疗COVID-19，持谨慎意见

2021-03-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）

2021-03-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

礼来的donanemab治疗阿尔茨海默症，结果好坏参半

2021-03-17

爆笑小医 (审核中...)

前往app查看评论内容

#EMA#

J Hematol Oncol：KMT2家族基因突变可预测癌症患者对免疫检查点治疗的反应性

2021-03-07

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA接受Somatrogon的市场营销申请，以治疗生长激素缺乏症患儿

2021-03-01

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

20价肺炎球菌疫苗，即将获得EMA的批准

2021-02-28

docwu2019 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率

2021-02-25

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Neurol：Tau蛋白单克隆抗体Tilavonemab对进行性核上性麻痹治疗无效！

2021-02-24

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Sparsentan治疗IgA肾病（IgAN），EMA已授予Sparsentan“孤儿药称号”

2021-02-22

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

胃肠道间质瘤（GIST）的治疗或迎新突破，EMA授予Ilixadencel“孤儿药资格”

2021-02-22

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著

2021-02-09

科室
- - 订阅+
  - 更多科室
工具
服务